SI3395340T1 - Hitrotopna formulacija, ki vsebuje cinakalcet HCL - Google Patents

Hitrotopna formulacija, ki vsebuje cinakalcet HCL

Info

Publication number
SI3395340T1
SI3395340T1 SI200432474T SI200432474T SI3395340T1 SI 3395340 T1 SI3395340 T1 SI 3395340T1 SI 200432474 T SI200432474 T SI 200432474T SI 200432474 T SI200432474 T SI 200432474T SI 3395340 T1 SI3395340 T1 SI 3395340T1
Authority
SI
Slovenia
Prior art keywords
rapid dissolution
cinacalcet hcl
dissolution formulation
formulation
cinacalcet
Prior art date
Application number
SI200432474T
Other languages
English (en)
Inventor
Francisco J. Alvarez
Tzuchi R. Ju
Hung-Ren H. Lin
Glen Cary Lawrence
Original Assignee
Amgen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3395340(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen, Inc. filed Critical Amgen, Inc.
Publication of SI3395340T1 publication Critical patent/SI3395340T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200432474T 2003-09-12 2004-09-10 Hitrotopna formulacija, ki vsebuje cinakalcet HCL SI3395340T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
EP18175499.5A EP3395340B8 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of cinacalcet hcl

Publications (1)

Publication Number Publication Date
SI3395340T1 true SI3395340T1 (sl) 2019-08-30

Family

ID=34434844

Family Applications (6)

Application Number Title Priority Date Filing Date
SI200432474T SI3395340T1 (sl) 2003-09-12 2004-09-10 Hitrotopna formulacija, ki vsebuje cinakalcet HCL
SI200432018T SI1663182T2 (sl) 2003-09-12 2004-09-10 Hitro raztapljajoča se formulacija cinakalceta HCI
SI200432472T SI3260117T1 (sl) 2003-09-12 2004-09-10 Hitrotopna formulacija, ki vsebuje cinakelcet HCL
SI200432475T SI3395338T1 (sl) 2003-09-12 2004-09-10 Hitrotopna formulacija, ki vsebuje cinakalcet HCL
SI200432416T SI2821067T1 (sl) 2003-09-12 2004-09-10 Hitro razprševalna formulacija cinakalceta
SI200432473T SI3395339T1 (sl) 2003-09-12 2004-09-10 Hitrotopna formulacija, ki vsebuje cinakalcet HCL

Family Applications After (5)

Application Number Title Priority Date Filing Date
SI200432018T SI1663182T2 (sl) 2003-09-12 2004-09-10 Hitro raztapljajoča se formulacija cinakalceta HCI
SI200432472T SI3260117T1 (sl) 2003-09-12 2004-09-10 Hitrotopna formulacija, ki vsebuje cinakelcet HCL
SI200432475T SI3395338T1 (sl) 2003-09-12 2004-09-10 Hitrotopna formulacija, ki vsebuje cinakalcet HCL
SI200432416T SI2821067T1 (sl) 2003-09-12 2004-09-10 Hitro razprševalna formulacija cinakalceta
SI200432473T SI3395339T1 (sl) 2003-09-12 2004-09-10 Hitrotopna formulacija, ki vsebuje cinakalcet HCL

Country Status (30)

Country Link
US (7) US7829595B2 (sl)
EP (8) EP2821067B1 (sl)
JP (3) JP5026077B2 (sl)
KR (1) KR101332058B1 (sl)
CN (1) CN1946382B (sl)
AR (1) AR045637A1 (sl)
AU (1) AU2004279318C1 (sl)
BR (2) BR122018013029B1 (sl)
CA (1) CA2536487C (sl)
CY (5) CY1119609T1 (sl)
DE (1) DE19164145T1 (sl)
DK (6) DK3395338T3 (sl)
EA (1) EA013425B1 (sl)
ES (7) ES2812198T1 (sl)
HR (1) HRP20130114T4 (sl)
HU (5) HUE044279T2 (sl)
IL (1) IL173737A (sl)
IS (1) IS3027B (sl)
MX (1) MXPA06002616A (sl)
MY (1) MY142046A (sl)
NO (1) NO335739B1 (sl)
NZ (1) NZ545498A (sl)
PL (6) PL3395338T3 (sl)
PT (6) PT2821067T (sl)
SG (1) SG146608A1 (sl)
SI (6) SI3395340T1 (sl)
TR (4) TR201910177T4 (sl)
TW (1) TWI344363B (sl)
WO (1) WO2005034928A1 (sl)
ZA (1) ZA200602710B (sl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
HUE044279T2 (hu) 2003-09-12 2019-10-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
EP2489659B1 (en) 2004-06-24 2017-12-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
ATE443038T1 (de) * 2005-05-16 2009-10-15 Teva Pharma Verfahren zur herstellung von cinacalcet hydrochlorid
CN101180261A (zh) * 2005-05-23 2008-05-14 特瓦制药工业有限公司 用于制备盐酸西那卡塞晶型ⅰ的方法
MX2007000982A (es) * 2005-05-23 2007-04-16 Teva Pharma Clorhidrato de cinacalcet amorfo y preparacion del mismo.
EP1884242B1 (en) 2005-05-26 2013-04-17 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical composition comprising lurasidone
JP5244597B2 (ja) * 2005-09-02 2013-07-24 アムジエン・インコーポレーテツド カルシリティック化合物またはカルシウム模倣性化合物を用いて腸液バランスを調節する方法
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
ES2790700T3 (es) 2005-12-28 2020-10-28 Vertex Pharma Composiciones farmacéuticas de la forma amorfa de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida
ES2904546T3 (es) 2006-02-03 2022-04-05 Opko Renal Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
WO2007112280A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
KR20090025189A (ko) * 2006-04-27 2009-03-10 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 염기의 제조 방법
CA2649245A1 (en) * 2006-04-27 2007-11-08 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
PL2679228T3 (pl) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
EP2069285A1 (en) * 2006-06-27 2009-06-17 Sandoz AG Amorphous form of cinacalcet
WO2008027522A2 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Solid composites of a calicum receptor-active compound
EP1968932A1 (en) * 2006-11-20 2008-09-17 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
DK2481400T3 (da) 2007-04-25 2014-09-29 Opko Ip Holdings Ii Inc Orale præparater med kontrolleret frigivelse omfattende en vitamin D-forbindelse og en voksagtig bærer
AU2008269181B2 (en) 2007-06-21 2014-04-17 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
US20090093652A1 (en) * 2007-08-16 2009-04-09 Michal Rafilovich Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
EP2300415A2 (en) * 2008-05-05 2011-03-30 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl¨-1-aminopropane derivative
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
JP2012503613A (ja) * 2008-09-25 2012-02-09 ラシオファルム ゲーエムベーハー コンパクト化シナカルセット
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
BRPI1011506B8 (pt) 2009-03-20 2021-05-25 Vertex Pharma processo para a fabricação de moduladores de regulador de condutância de transmembrana de fibrose cística
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2435400A2 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
LT2552484T (lt) 2010-03-29 2020-04-27 Opko Ireland Global Holdings, Ltd. Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
EP2603215A4 (en) 2010-08-11 2015-08-05 Philadelphia Health & Educatio NEW DOPAMINERGIC D3 RECEPTOR AGONISTS FOR TREATING DYSKINESIA IN PARKINSON'S DISEASE
SI2642980T1 (sl) * 2010-11-23 2020-07-31 Amgen Inc. Pediatrične formulacije
US20130267516A1 (en) 2010-11-26 2013-10-10 Leo Pharma A/S Substituted cyclopentyl-azines as casr-active compounds
US20130245084A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
US20130261132A1 (en) 2010-11-26 2013-10-03 Leo Pharma A/S Calcium-sensing receptor-active compounds
CN103228619A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 钙传感受体活性化合物
AU2012364736A1 (en) * 2011-12-19 2014-07-24 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
WO2013107503A1 (en) 2012-01-17 2013-07-25 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
ES2547577T3 (es) * 2012-11-09 2015-10-07 K.H.S. Pharma Holding Gmbh Formulaciones de liberación inmediata de cinacalcet
CN105050708A (zh) 2012-11-14 2015-11-11 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
BR112015014430B1 (pt) * 2012-12-21 2022-08-30 Synthon B.V. Composição em comprimido
JP2016508504A (ja) 2013-02-01 2016-03-22 サンタ マリア バイオセラピューティクス インコーポレイテッド 対象に対する抗アクチビン−ａ化合物の投与
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3013324A1 (en) 2013-06-26 2016-05-04 Jubilant Generics Limited Disintegrant free composition of cinacalcet
EP3116487A1 (en) * 2014-03-14 2017-01-18 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
EP3193925A2 (en) * 2014-08-07 2017-07-26 OPKO Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin d
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
CN108883120A (zh) 2016-03-28 2018-11-23 欧普科爱尔兰环球控股有限公司 维生素d治疗方法
CA3019508A1 (en) 2016-03-31 2017-10-05 Intercept Pharmaceuticals, Inc. Oral preparation having exceptional elutability
EP3668493A4 (en) * 2017-08-16 2021-08-25 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITIONS WITH CINACALCET HYDROCHLORIDE AND ONE OR MORE BINDERS
EP3773533A1 (en) 2018-03-30 2021-02-17 FTF Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
WO2021173533A1 (en) * 2020-02-29 2021-09-02 Kempharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
NZ226696A (en) 1987-11-02 1991-10-25 Merck & Co Inc Tablet composition comprising a phthalazine acetic acid derivative as the active ingredient present in from 83-88 wt%
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
AU4664889A (en) 1988-11-30 1990-06-26 Schering Corporation Sustained release diltiazem formulation
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
RU2147574C1 (ru) 1991-08-23 2000-04-20 Эн-Пи-Эс Фармасьютикалз, Инк. Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1995011221A1 (en) 1991-08-23 1995-04-27 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP4143118B2 (ja) 1993-02-23 2008-09-03 ブリガム・アンド・ウイミンズ・ホスピタル・インコーポレイテッド カルシウム受容体活性化分子およびその関連物
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
TW398975B (en) * 1994-07-22 2000-07-21 Lilly Co Eli Pharmaceutical composition for inhibiting bone loss
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
DK1203761T3 (da) * 1994-12-08 2005-04-11 Nps Pharma Inc Calciumreceptoraktive forbindelser
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
DK0907631T3 (da) 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
KR100860655B1 (ko) 1996-07-08 2008-09-26 기린 파마 가부시끼가이샤 칼슘 수용체 활성 화합물
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
ATE219658T1 (de) 1998-03-06 2002-07-15 Eurand Int Schnell zerfallende tablette
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
WO2000021910A2 (en) 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
ATE275342T1 (de) * 1998-11-23 2004-09-15 Monsanto Technology Llc Hochkonzentrierte wässrige glyphosatzusammensetzungen
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
CA2394222A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001078725A2 (en) * 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
US20040034039A1 (en) 2000-09-22 2004-02-19 Yoshinori Nakano Solid preparations
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (sl) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
WO2003086343A2 (en) 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20040082588A1 (en) 2002-09-30 2004-04-29 Schering Corporation Methods for treating disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
HUE044279T2 (hu) 2003-09-12 2019-10-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
PT1713489E (pt) 2004-08-23 2011-03-03 Teva Pharma Forma cristalina de ibandronato de sódio e processos para a sua preparação
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
WO2009111876A1 (en) 2008-03-11 2009-09-17 The University Of Western Ontario System and method for magnetic resonance imaging

Also Published As

Publication number Publication date
CA2536487C (en) 2011-10-25
NO335739B1 (no) 2015-02-02
PT2821067T (pt) 2017-12-01
SI3395338T1 (sl) 2019-08-30
EP3395339A1 (en) 2018-10-31
PL3395339T3 (pl) 2019-09-30
IS8324A (is) 2006-02-23
TR201910180T4 (tr) 2019-07-22
PT3260117T (pt) 2019-07-04
ES2401769T3 (es) 2013-04-24
EP3260117A1 (en) 2017-12-27
SI1663182T2 (sl) 2020-02-28
EP3578175B1 (en) 2022-11-30
CA2536487A1 (en) 2005-04-21
DK3395339T3 (da) 2019-07-22
HUE044822T2 (hu) 2019-11-28
TWI344363B (en) 2011-07-01
US20050147669A1 (en) 2005-07-07
NZ545498A (en) 2010-04-30
TR201909267T4 (tr) 2019-07-22
SI2821067T1 (sl) 2018-03-30
EP1663182A1 (en) 2006-06-07
US20210052518A1 (en) 2021-02-25
US20110136915A1 (en) 2011-06-09
JP5940120B2 (ja) 2016-06-29
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05
EA200600566A1 (ru) 2006-08-25
CN1946382B (zh) 2010-12-08
DK3395338T3 (da) 2019-07-22
SI3395339T1 (sl) 2019-08-30
PT3395340T (pt) 2019-07-15
JP5026077B2 (ja) 2012-09-12
BR122018013029B1 (pt) 2022-04-12
DE19164145T1 (de) 2021-04-29
JP2015007089A (ja) 2015-01-15
IL173737A0 (en) 2006-07-05
AU2004279318B2 (en) 2010-02-25
EP1663182B2 (en) 2019-11-20
PL2821067T3 (pl) 2018-02-28
EP3260117B1 (en) 2019-04-17
EP2821067B1 (en) 2017-10-25
HRP20130114T1 (en) 2013-03-31
US20200222340A1 (en) 2020-07-16
EP2821067A1 (en) 2015-01-07
PL3395340T3 (pl) 2019-10-31
EP3395338A1 (en) 2018-10-31
TR201910177T4 (tr) 2019-08-21
PT1663182E (pt) 2013-03-14
ES2655435T3 (es) 2018-02-20
EP3395339B1 (en) 2019-04-17
PL1663182T5 (pl) 2020-07-27
US20180243238A1 (en) 2018-08-30
HUE035596T2 (en) 2018-05-28
MY142046A (en) 2010-08-30
IS3027B (is) 2021-03-15
IL173737A (en) 2012-04-30
JP5849015B2 (ja) 2016-01-27
CY1122259T1 (el) 2020-11-25
EP3395340A1 (en) 2018-10-31
CN1946382A (zh) 2007-04-11
US20190117592A1 (en) 2019-04-25
PL3395338T3 (pl) 2019-10-31
EA013425B1 (ru) 2010-04-30
US7829595B2 (en) 2010-11-09
TW200518743A (en) 2005-06-16
ES2812198T1 (es) 2021-03-16
ES2734057T3 (es) 2019-12-04
DK3395340T3 (da) 2019-07-15
TR201910447T4 (tr) 2019-08-21
AU2004279318C1 (en) 2020-06-25
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
JP2007505108A (ja) 2007-03-08
SG146608A1 (en) 2008-10-30
US9375405B2 (en) 2016-06-28
CY1121820T1 (el) 2020-07-31
ES2401769T5 (es) 2020-07-01
DK3260117T3 (da) 2019-07-01
WO2005034928A1 (en) 2005-04-21
SI3260117T1 (sl) 2019-08-30
HUE045411T2 (hu) 2019-12-30
DK2821067T3 (en) 2017-12-04
ES2737348T3 (es) 2020-01-13
HUE044279T2 (hu) 2019-10-28
JP2012197280A (ja) 2012-10-18
SI1663182T1 (sl) 2013-05-31
ES2735216T3 (es) 2019-12-17
AR045637A1 (es) 2005-11-02
NO20061640L (no) 2006-06-12
EP3395338B1 (en) 2019-05-01
ZA200602710B (en) 2007-04-25
CY1121812T1 (el) 2020-07-31
CY1119609T1 (el) 2018-04-04
PT3395339T (pt) 2019-07-15
PT3395338T (pt) 2019-07-23
BRPI0414254A (pt) 2006-11-07
US20160338975A1 (en) 2016-11-24
BRPI0414254B8 (pt) 2021-05-25
PL3260117T3 (pl) 2019-10-31
BRPI0414254B1 (pt) 2021-03-02
AU2004279318A1 (en) 2005-04-21
EP3260117B8 (en) 2019-11-27
PL1663182T3 (pl) 2013-06-28
EP3395340B1 (en) 2019-04-17
EP3395339B8 (en) 2019-12-11
ES2735226T3 (es) 2019-12-17
CY1121814T1 (el) 2020-07-31
DK1663182T4 (da) 2020-02-17
DK1663182T3 (da) 2013-04-15
KR20070017460A (ko) 2007-02-12
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
EP3395340B8 (en) 2019-12-11
EP2316442A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
SI3395340T1 (sl) Hitrotopna formulacija, ki vsebuje cinakalcet HCL
EP1684689A4 (en) VENLAFAXINE PREPARATION WITH PROLONGED RELEASE
GB0323908D0 (en) Pharmaceutical foam formulation
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
EG24479A (en) Modified release pharmaceutical formulation
GB0318448D0 (en) Formulation
GB0316206D0 (en) Pharmaceutical formulation
IL165069A0 (en) Immediate release pharmaceutical formulation
IL164077A0 (en) Sustained release formulation of tramadol
GB0312195D0 (en) Formulation
GB0320522D0 (en) Formulation
GB0303876D0 (en) Formulation
GB0310881D0 (en) Pharmaceutical formulation
GB0318663D0 (en) Rolling formulation
IL159780A0 (en) Extended release venlafaxine tablet formulation
ZA200510326B (en) Dimeticone-containing sustaned formulation
GB0316538D0 (en) Formulation
GB0308978D0 (en) Formulation
GB0302435D0 (en) Pharmaceutical formulation